The Medicines Company (MDCO) – Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for The Medicines Company (NASDAQ: MDCO):

  • 3/20/2017 – The Medicines Company had its “positive” rating reaffirmed by analysts at HC Wainwright.
  • 3/18/2017 – The Medicines Company had its “buy” rating reaffirmed by analysts at JPMorgan Chase & Co..
  • 3/1/2017 – The Medicines Company had its price target raised by analysts at Jefferies Group LLC from $49.00 to $62.00. They now have a “positive” rating on the stock.
  • 3/1/2017 – The Medicines Company had its “buy” rating reaffirmed by analysts at Royal Bank of Canada.
  • 2/27/2017 – The Medicines Company had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock, up previously from $57.00.

The Medicines Company (NASDAQ:MDCO) traded up 4.144% during midday trading on Monday, hitting $50.385. The stock had a trading volume of 3,117,261 shares. The firm has a 50 day moving average price of $49.08 and a 200 day moving average price of $39.53. The Medicines Company has a one year low of $29.48 and a one year high of $55.28. The stock’s market cap is $3.56 billion.

In related news, CFO William Bernard O’connor sold 25,833 shares of the business’s stock in a transaction that occurred on Tuesday, February 7th. The stock was sold at an average price of $46.20, for a total transaction of $1,193,484.60. Following the sale, the chief financial officer now owns 30,935 shares of the company’s stock, valued at $1,429,197. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 7.90% of the stock is owned by insiders.

The Medicines Company is a global biopharmaceutical company. The Company’s marketed products include Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin).

5 Day Chart for NASDAQ:MDCO

Receive News & Ratings for The Medicines Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Mattel CEO Promises Growth Following Sales Slump
Mattel CEO Promises Growth Following Sales Slump
Burberry Misses Estimates on Sales
Burberry Misses Estimates on Sales
Snapchat: CEO Did Not Label India as Being Poor
Snapchat: CEO Did Not Label India as Being Poor
Credit Suisse Slashes Bonuses by 40%
Credit Suisse Slashes Bonuses by 40%
Daily Mail to Pay Melania Trump $3 Million
Daily Mail to Pay Melania Trump $3 Million
New York Approves Free College Tuition
New York Approves Free College Tuition


© 2006-2017 Ticker Report. Google+.